(Original Signature of Member)
114TH CONGRESS 1ST SESSION H.R.
To provide for the rescheduling of marihuana, the medical use of marihuana in accordance with State law, and the exclusion of cannabidiol from the definition of marihuana, and for other purposes.
IN THE HOUSE OF REPRESENTATIVES
Mr. Griffith introduced the following bill; which was referred to the Committee on
A BILL
To provide for the rescheduling of marihuana, the medical use of marihuana in accordance with State law, and the exclusion of cannabidiol from the definition of marihuana, and for other purposes.
1 Be it enacted by the Senate and House of Representa-
2 tives of the United States of America in Congress assembled,
3 SECTION 1. SHORT TITLE.

This Act may be cited as the "Compassionate Access

6 SEC. 2. AVAILABILITY OF MARIHUANA FOR MEDICAL USE.

4

7

5 Act".

(a) Rescheduling.—

1	(1) RECOMMENDATION BY HHS.—Not later
2	than 180 days after the date of enactment of this
3	Act, the Secretary of Health and Human Services,
4	in consultation with the Institute of Medicine of the
5	National Academy of Sciences, shall submit to the
6	Administrator of the Drug Enforcement Administra-
7	tion a recommendation to transfer marihuana from
8	schedule I under section 202 of the Controlled Sub-
9	stances Act (21 U.S.C. 812) to a schedule under
10	such section 202 other than schedule I.
11	(2) Final Rule.—Not later than one year
12	after the date of enactment of this Act, the Adminis-
13	trator of the Drug Enforcement Administration
14	shall, taking into consideration the recommendation
15	under paragraph (1), issue a final rule to transfer
16	marihuana from schedule I under section 202 of the
17	Controlled Substances Act (21 U.S.C. 812) to a
18	schedule under such section other than schedule I.
19	(b) Cannabidiol.—
20	(1) In General.—Paragraph (16) of section
21	102 of the Controlled Substances Act (21 U.S.C.
22	802) is amended—
23	(A) by striking "(16) The" and inserting
24	"(16)(A) The"; and
25	(B) by adding at the end the following:

1	"(B) Cannabidiol—
2	"(i) is excluded from the definition of mar-
3	ihuana under subparagraph (A); and
4	"(ii) shall not be treated as a controlled
5	substance under this Act.".
6	(2) Definition.—Section 102 of the Con-
7	trolled Substances Act (21 U.S.C. 802), as amended
8	by paragraph (1), is further amended by adding at
9	the end the following:
10	"(57) The term 'cannabidiol' means the sub-
11	stance cannabidiol, as derived from marihuana or
12	synthetically formulated, that contains not greater
13	than 0.3 percent delta-9-tetrahydrocannabinol on a
14	dry weight basis.".
15	(3) Cannabidiol determination by the
16	STATES.—Section 201 of the Controlled Substances
17	Act (21 U.S.C. 811) is amended by adding at the
18	end the following:
19	"(j) Cannabidiol Determination.—If a person
20	grows or processes marihuana for purposes of making
21	cannabidiol in accordance with State law, the marihuana
22	shall be deemed to meet the concentration limitation under
23	section 102(57), unless the Attorney General determines
24	that the State law is not reasonably calculated to ensure

1	that marihuana grown or processed for purposes of mak-
2	ing cannabidiol meets such concentration limitation.".
3	(c) REGULATION UNDER STATE LAW.—
4	(1) In general.—In a State in which mari-
5	huana may be prescribed by a physician for medical
6	use under applicable State law, no provision of the
7	Controlled Substances Act (21 U.S.C. 801 et seq.)
8	or of the Federal Food, Drug, and Cosmetic Act (21
9	U.S.C. 301 et seq.) shall prohibit or otherwise re-
10	strict in such State in accordance with such State
11	law—
12	(A) the prescription of marihuana by a
13	physician for medical use;
14	(B) an authorized patient under such State
15	law from obtaining, possessing, transporting, or
16	using marihuana for that patient's medical use;
17	(C) a caregiver for an authorized patient
18	from obtaining, possessing, or transporting
19	marihuana, as authorized under such State law,
20	for the medical use of such authorized patient;
21	(D) the legally recognized parent or guard-
22	ian of a minor who is an authorized patient
23	from obtaining, possessing, or transporting
24	marihuana, as authorized under such State law,
25	for the medical use of such minor;

1	(E) an entity from producing, processing,
2	or otherwise manufacturing marihuana for med-
3	ical use, as authorized under such State law;
4	(F) an entity from distributing marihuana
5	for medical use, as authorized under such State
6	law;
7	(G) a pharmacy or other health care pro-
8	vider from dispensing marihuana to an author-
9	ized patient for medical use, as authorized
10	under such State law; or
11	(H) a laboratory or other entity from per-
12	forming safety, quality, or efficacy testing of
13	marihuana for medical use, as authorized under
14	such State law or under Federal law.
15	(2) Cannabidiol.—Notwithstanding the exclu-
16	sion of cannabidiol from the definition of marihuana
17	in section 102 of the Controlled Substances Act (21
18	U.S.C. 802), as amended, and section 5 of this Act,
19	this subsection applies with respect to cannabidiol,
20	as defined in such section 102, to the same extent
21	and in the same manner as this subsection applies
22	with respect to marihuana.

1	SEC. 3. RESEARCH INTO POTENTIAL MEDICINAL USES OF
2	MARIHUANA.
3	(a) In General.—Not later than 180 days after the
4	date of enactment of this Act, the Attorney General shall
5	delegate responsibility under section 303(f) of the Con-
6	trolled Substances Act (21 U.S.C. 823(f)) for control over
7	access to marihuana for research into its potential medic-
8	inal uses to an agency of the Executive Branch that is
9	not focused on researching the addictive properties of sub-
10	stances. Such agency shall take appropriate actions to en-
11	sure that an adequate supply of marihuana is available
12	for such medicinal research.
13	(b) Consideration of Other Research in
14	Scheduling.—Research that is performed in a scientif-
15	ically sound manner in a State where marihuana or
16	cannabidiol is legal for medical purposes, and in accord-
17	ance with such State's law, but that does not use mari-
18	huana from federally approved sources, may be considered
19	for purposes of rescheduling marihuana under section 202
20	of the Controlled Substances Act (21 U.S.C. 812).
21	SEC. 4. RELATION OF ACT TO CERTAIN PROHIBITIONS RE-
22	LATING TO SMOKING.
23	This Act does not affect any Federal, State, or local
24	law regulating or prohibiting smoking in public.
25	SEC. 5. DEFINITIONS.
26	In this Act:

1	(1) AUTHORIZED PATIENT.—The term "author-
2	ized patient" means an individual using marihuana
3	in accordance with a prescription by a physician for
4	medical use.
5	(2) Marihuana.—Except as provided in sec-
6	tion 2(c)(2), the term "marihuana" has the meaning
7	given to such term in section 102 of the Controlled
8	Substances Act (21 U.S.C. 802), as amended by sec-
9	tion 2(b).
10	(3) Physician.—The term "physician" means
11	a practitioner of medicine, who—
12	(A) graduated from a college of medicine
13	or osteopathy; and
14	(B) is licensed to practice medicine by the
15	appropriate State board.
16	(4) Prescription.—The term "prescription"
17	means an instruction written by a medical physician
18	in accordance with applicable State law that author-
19	izes the provision of a medicine or treatment to a
20	patient.
21	(5) State.—The term "State" includes the
22	District of Columbia, Puerto Rico, and any other
23	territory or possession of the United States.